Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3525-3534

  Vaziri, Nosratola D ^a   Kim, Hyun Ju ^a   Moradi, Hamid ^a   Farmand, Farbod ^a   Navab, Kaveh ^b   Navab, Mohamad ^b   Hama, Susan ^b   Fogelman, Alan M ^b   Quiroz, Yasmir ^c   Rodriguez Iturbe, Bernardo ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Atherosclerosis; Chronic kidney disease; Hyperlipidaemia; Inflammation; Oxidative stress

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CYCLOOXYGENASE 2; DRINKING WATER; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; CCL2 PROTEIN, MOUSE; D 4F PEPTIDE; D-4F PEPTIDE; PROTEASE NEXIN I; SERPINE2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; FEMALE; FOAM CELL; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY HYPERTROPHY; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME; UPREGULATION; ANIMAL; BIOSYNTHESIS; HYPERLIPIDEMIA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; CHEMOKINE CCL2; FEMALE; HYPERLIPIDEMIAS; KIDNEY DISEASES; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; NADPH OXIDASE; SERPIN E2;

EID: 79952199488     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq274     Document Type: Article

References (47)

1. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol 2006; 290: 262-272
2. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009; 22: 644-651
3. Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 1999; 71: 14-17
4. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005; 99: 87-93
5. Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 2008; 28: 723-731
6. Keane WF. The role of lipids in renal disease: Future challenges. Kidney Int Suppl 2000; 75: 27-31
7. Kim HJ, Moradi H, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol, Renal Physiol 2009; 296: 1297-1306
8. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183
9. Samuelson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915 (Pubitemid 27379464)
10. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919 (Pubitemid 27252762)
11. Muntner P, Coresh J, Smith C et al. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 2000; 58: 293-301 (Pubitemid 30429874)
12. Amatruda JM, Margolis S, Hutchins GM. Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch Pathol 1974; 98: 51-54
13. Majumdar A, Wheeler DC. Lipid abnormalities in renal disease. J R Soc Med 2000; 93: 178-182 (Pubitemid 30218868)
14. Ghiselli G, Schaefer EJ, Gascon P et al. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 1981; 214: 1239-1241 (Pubitemid 12167328)
15. Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353
16. Zadelaar S, Kleemann R, Verschuren L et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-1721 (Pubitemid 47207165)
17. Wen M, Segerer S, Dantas M et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002; 82: 999-1006
18. Bruneval P, Bariéty J, Bélair MF et al. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002; 17: 2099-2107 (Pubitemid 35446664)
19. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889-2895 (Pubitemid 30415877)
20. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: Evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000; 20: 1116-1122 (Pubitemid 30207591)
21. Cominacini L, Pasini AF, Garbin U et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 275: 12633-12638 (Pubitemid 30241412)
22. Mehta JL, Chen J, Hermonat PL et al. Lectin-like, oxidized lowdensity lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45 (Pubitemid 41814809)
23. Mahley RW, Huang Y. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999; 10: 207-217 (Pubitemid 29405911)
24. Langer C, Huang Y, Cullen Pet al. Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med 2000; 78: 217-227 (Pubitemid 30432012)
25. Mahley RW, Rall SCJr. Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537
26. Tang J, Raines EW. Are suppressors of cytokine signaling proteins recently identified in atherosclerosis possible therapeutic targets? Trends Cardiovasc Med 2005; 15: 243-249 (Pubitemid 41437906)
27. Navab M, Anantharamaiah GM, Hama S et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-1432 (Pubitemid 40923363)
28. Navab M, Anantharamaiah GM, Reddy ST et al. Oral D-4F causes formation of pre-b high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-3220
29. Li X, Chyu KY, Faria Neto JR et al. Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701-1705 (Pubitemid 39297996)
30. Ou J, Ou Z, Jones DW et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-2341 (Pubitemid 36578505)
31. Ou J, Wang J, Xu H et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005; 97: 1190-1197
32. Van Lenten BJ,Wagner AC, Nayak DP et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103: 2283-2288 (Pubitemid 32433719)
33. Charles-Schoeman C, Banquerigo ML, Hama S et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008; 127: 234-244
34. Navab M, Anantharamaiah GM, Fogelman AM. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 2008; 18: 61-66 (Pubitemid 351282495)
35. Buga GM, Frank JS, Mottino GA et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res 2008; 49: 192-205
36. Sakurai H, Hisada Y, Ueno M et al. Activation of transcription factor NF-?B in experimental glomerulonephritis in rats. Biochim Biophys Acta 1996; 1316: 132-138 (Pubitemid 26193966)
37. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A et al. Evolution of renal interstitial inflammation and NF-kB activation in spontaneously hypertensive rats. Am J Nephrol 2004; 24: 587-594 (Pubitemid 40187016)
38. Rodriguez-Iturbe B, Quiroz Y, Nava M et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol, Renal Physiol 2002; 282: F191-F201 (Pubitemid 34654549)
39. Cheng HF, Harris RC. Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and post-transcriptional mechanisms: Role of p38-mediated pathways. J Biol Chem 2002; 277: 45638-45643 (Pubitemid 36159175)
40. Vaziri ND, Rodríguez-Iturbe B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593 (Pubitemid 44465680)
41. Goncalves AR, Fujihara CK, Mattar AL et al. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: Strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286: 945-954
42. Kramer BK, Kammerl MC, Komhoff M. Renal cyclooxygenase-2 (COX-2): Physiological, pathophysiological, and clinical implications. Kidney Blood Press Res 2004; 27: 43-62 (Pubitemid 38186474)
43. Ota T, Takamura T, Ando H et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-851 (Pubitemid 36831414)
44. Reddy MA, Adler SG, Kim YS et al. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol, Renal Physiol 2002; 283: 985-994
45. Kiritoshi S, Nishikawa T, Sonoda K et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: Potential role in diabetic nephropathy. Diabetes 2003; 52: 2570-2577 (Pubitemid 37210547)
46. Komers R, Lindsley JN, Oyama TT et al. Effects of cyclooxygenase- 2 (COX-2) inhibition on plasma and renal renin in diabetes. J Lab Clin Med 2002; 140: 351-357 (Pubitemid 35302028)
47. Vaziri ND, Moradi H, Pahl MV et al. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009; 76: 437-344